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High-intensity focused ultrasound (HIFU) provides a potential noninvasive alternative to conventional therapies. We report our
preliminary experience from clinical trials designed to evaluate the safety and feasibility of a novel, extracorporeal HIFU device for the
treatment of liver and kidney tumours in a Western population. The extracorporeal, ultrasound-guided Model-JC Tumor Therapy
System (HAIFUt Technology Company, China) has been used to treat 30 patients according to four trial protocols. Patients with
hepatic or renal tumours underwent a single therapeutic HIFU session under general anaesthesia. Magnetic resonance imaging 12
days after treatment provided assessment of response. The patients were subdivided into those followed up with further imaging
alone or those undergoing surgical resection of their tumours, which enabled both radiological and histological assessment. HIFU
exposure resulted in discrete zones of ablation in 25 of 27 evaluable patients (93%). Ablation of liver tumours was achieved more
consistently than for kidney tumours (100 vs 67%, assessed radiologically). The adverse event profile was favourable when compared
to more invasive techniques. HIFU treatment of liver and kidney tumours in a Western population is both safe and feasible. These
findings have significant implications for future noninvasive image-guided tumour ablation.
British Journal of Cancer (2005) 93, 890–895. doi:10.1038/sj.bjc.6602803 www.bjcancer.com
Published online 27 September 2005
& 2005 Cancer Research UK
Keywords: ablation; clinical; HIFU; kidney; liver
                                               
Over the last decade, minimally invasive therapies have developed
to provide a role in the ablation of solid tumour deposits in the
liver and kidney. Radiofrequency waves (Gervais et al, 2003),
cryotherapy (Sotsky and Ravikumar, 2002), lasers (Vogl et al,
2004), microwave energy (Shibata et al, 2002), ethanol injection
(Livraghi et al, 1995) and high-intensity focused ultrasound
(HIFU) (Kennedy, 2005) have all been used to ablate tumours;
however, HIFU remains the only modality to be completely
extracorporeal.
Ultrasound may pass harmlessly through human tissue, yet
when focused at high intensities, sufficient energy may be
deposited to produce a well-demarcated volume of coagulation
necrosis, independent of soft tissue type (Hill et al, 1994). This has
been known since the 1940s (Lynn et al, 1942); however, it is only
recently that advances in imaging have allowed accurate placement
of the acoustic focus and thus its clinical exploitation (Kennedy
et al, 2003).
The most widely used clinical extracorporeal device is the
Model-JC HIFU System (Chongqing HAIFUt Company). The
device has been used in China and the Far East since 1997 (Wu
et al, 2004). Recent data suggest a survival advantage when it is
used in combination with trans-arterial chemoembolisation
(TACE) in patients with unresectable hepatocellular carcinoma
(Wu et al, 2005a). There is also data to show that HIFU has a role
to play in the relief of intractable pain relating to pancreatic cancer
(Wu et al, 2005b). We report results from early phase II studies
investigating the safety and feasibility of extracorporeal HIFU for
the treatment of liver and kidney tumours in a Western population
using this system.
PATIENTS AND METHODS
All trials were approved by the Oxfordshire Clinical Research
Ethics Committee and conformed to GCP guidelines. Patients
included both surgical and nonsurgical candidates and each
patient had one or more solid tumour deposits in either the liver
or kidney (see Figure 1). All patients were over 18 years old and
gave written informed consent to take part in the study. Previous
surgery, chemo- and biological therapy were permitted provided
that they had recovered from any related side effects. No patients
had received radiotherapy to the target region in the preceding 12
months. Patients were required to have normal bone marrow
function (haemoglobin X10gdl
 1, absolute neutrophil count
X1500mm
 3, platelet count X100000mm
 3), renal function
(urea and creatinine o2.5 times upper limit of laboratory normal
(ULN) range) and adequate hepatic reserve (prothrombin time
p1.5 times ULN, activated partial thromboplastin time p1.5 times
ULN, total bilirubin o1.5 times ULN, AST p3 times ULN, alkaline
phosphatase o2 times ULN, unless arising from the bone). All
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spatients required an American Society of Anaesthesiologists grade
of p2, and a World Health Organization performance status
of p1.
General exclusion criteria for all trials included: women who
were pregnant or nursing, clinical evidence of brain metastases,
subjects with tumours lying o5mm from vital structures,
concurrent antiarrhythmic, anticoagulant or immunosuppressive
medication, permanent implanted pacemakers and those who had
previously documented severe intra-abdominal adhesions.
The Model-JC HIFU System (Chongqing HAIFUt Company)
was used in all cases and has been described previously (Kennedy
et al, 2004). Briefly, the device has a 12cm diameter, single
element, piezo-ceramic transducer fronted by acoustic lenses of
varying focal lengths, driven at 0.8 or 1.6MHz. An AU3 US
imaging device (Esaote, Genoa, Italy) is mounted coaxially with the
high-energy transducer allowing treatment to be guided in real
time.
Patients received gadolinium contrast-enhanced (CE) magnetic
resonance imaging (MRI), baseline blood tests and symptom
review prior to HIFU therapy. Each patient received a single HIFU
treatment session under general anaesthesia; a double lumen
endotracheal tube allowed single lung ventilation, thus minimising
organ movement during respiration. Treatment consisted of a
combination of single and multiple overlapping ultrasonic pulses
directed to the target tumour. According to the trial protocols, a
single tumour, or part of a single tumour, was selected for ablation.
Grey scale changes visualised on B-mode diagnostic ultrasound
during treatment allowed assessment of tissue response. At the
time of HIFU treatment, the estimated dimensions of the ablated
region were recorded in the anteroposterior (AP), transverse and
cranial–caudal dimensions. This provided the reference value by
which both radiological and histological observations were
assessed.
Radiological follow-up for all patients was at 12 days (or within
3 days of day 12) with a further CE-MRI. The MRI sequences used
in the evaluation and quantification of ablation varied according to
the target organ. Liver tumours were assessed using the
reformatted FAME (Fast Acquisition, Multiple Excitation) se-
quences 1min postinjection of intravenous gadolinium contrast
agent. Kidney tumours were assessed using subtraction films,
where the FAME precontrast series was taken from the 1min
postcontrast series. Repeat blood analyses and symptom reviews
took place on days 1, 2 and 12. Surgical resection of the tumours in
groups 2 and 4 took place within 14 days of HIFU treatment.
Patients in groups 1 and 3 had a symptom review on day 30 after
treatment.
Primary end points of the study were adverse events and
variations in clinical laboratory data during the first 28 days
following treatment (or until surgical resection). Device-related
adverse events were graded according to the Common Toxicity
Criteria (Version 2, Final 1/30/98) where applicable.
Secondary end points were radiological and histological
assessment of response. Radiological response was evaluated in
terms of the presence and accuracy of ablation within the target
tumour. ‘Accuracy’ was assessed from the 12-day post-HIFU MRI
images. Where ablation was seen, the Radiologist commented on
whether the zone fell within the target tumour (‘good’) or outside
the target tumour (‘poor’). The size of any zone of coagulation
necrosis was measured – these were given both as short-axis
diameter (the minimum requirements according to the Working
Group on Image-Guided Tumour Ablation special report; Gold-
berg et al, 2003) and also area estimates derived from the AP and
transverse measurements. ‘Radiological response’ was derived
from a comparison between the maximal area of ablation seen on
MRI and the maximal intended area of ablation recorded at the
time of treatment. It should be noted that the intended area of
ablation did not necessarily equate to the patient’s total tumour
burden.
Pathological evaluation of the treated lesion followed surgery in
groups 2 and 4. At the time of surgery, the specimen was marked,
and oriented in a way that enabled histological slices to correspond
as far as possible with MRI slices. Sections (5mm) were cut and
photographed to allow semiquantitative assessment of histological
response. Microscopic confirmation of the effect of HIFU was
obtained by taking representative histological slides from areas,
which included interfaces between tissues of different macroscopic
appearance. These interfaces included those between any areas of
necrotic and nonnecrotic tumour, between viable tumour and
normal liver and between necrotic and viable liver. The assessment
compared the maximal area of ablation seen on macroscopic vital
staining with the maximal estimated area of ablation recorded at
the time of treatment.
RESULTS
Between November 2002 and August 2004, 30 patients (23 male,
seven female) were recruited with mean age 65 years (range 40–84
years). Of these, 22 patients had liver metastases (18 colorectal, one
breast, one lung and two adenocarcinoma of unknown primary).
All kidney tumours were renal cell carcinoma. All the patients were
treated with HIFU and were evaluable for adverse events.
Table 1 summarises the treatment parameters. During the
research period, treatment times were limited to approximately
2h. This constraint limited the extent to which a given tumour that
could be treated in any single HIFU session.
A total of 15 patients were treated with HIFU in group 1. One
treatment session was abandoned when the water reservoir
housing the treatment head leaked. One patient died 10 days after
HIFU of causes unrelated to the HIFU treatment. Although no
imaging was performed post-HIFU, the patient underwent post-
mortem examination and the results of this evaluable in terms of
histological response. As a result, 13 of the 15 patients have been
evaluated for MRI response to treatment. All 15 patients were
evaluable for device-related adverse events.
In the liver surgery group (group 2), the seven enrolled patients
all completed the HIFU treatment session and had both the pre-
and post-HIFU MRI. All were evaluable for device-related adverse
events. One patient did not proceed to surgery when further liver
metastases were discovered on pre-HIFU I.
Table 1 Patient treatment parameters
Mean Range
Anaesthetic time (min) 209 150–271
Patient positioning (min) 17 8–14
Time to locate tumour and plan treatment (min) 46 8–133
Treatment duration (min) 123 30–189
Total exposure (min) 20 0.2–43.5
30 patients
Liver tumours  Kidney tumours
22 patients  eight patients
Nonsurgical Surgical Nonsurgical Surgical
15 patients  seven patients three patients five patients
 Group 1 Group 2 Group 3 Group 4
Figure 1 Patient disposition.
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sIn group 3, two of the three patients had a complete HIFU
treatment session and were evaluable in terms of radiological
response. One session was terminated prematurely as bowel had
become interposed in the treatment field. All three were evaluable
in terms of adverse events.
All five patients in group 4 completed the HIFU treatment
session; however, on retrospective independent radiological
analysis, one patient was thought to have a renal scar rather than
a renal tumour. This patient did not proceed to surgical resection
and was excluded from the final radiological analysis.
Device-related adverse recorded for the trial patients are
summarised in Table 2. Although the majority of patients
experienced some discomfort, this was generally transitory. Those
requiring additional opiates were only administered them in the
immediate post-HIFU period. All patients felt well enough to be
discharged from hospital the following day as per the protocol.
The most common form of skin toxicity was the formation of a
blister or track at the treatment site, o1cm diameter. These were
typically 1 1mm across, as shown in Figure 2A and B. Skin
toxicity was treated with cool-packs and aloe gel: grade 1 toxicity
generally resolved by day 12 without further action. Grade 2
toxicity (partial thickness blister or burn 41cm diameter) also
required no further treatment, but took longer to resolve. No grade
3 skin toxicity was seen. Oedema at the treatment site was
transitory, generally resolving prior to discharge with no further
treatment. Four patients developed a mild fever during the first
24h after treatment, never above 401C. All fevers settled with
antipyretics and had resolved prior to discharge. One patient
experienced increased skin sensitivity at the treatment site, and a
further patient had some permanent subcutaneous thickening and
pigmentation at the treatment site.
There was a transient and clinically insignificant drop in
haemoglobin immediately after HIFU (mean decrease of 1.0gdl
 1
(range 0.9–3.2gdl
 1)). As there has been no blood loss associated
with the treatments, this is likely to be a dilutional artefact
following anaesthesia. A transient rise was also seen in white blood
counts immediately after treatment (mean increase of
1.71 10
 9l
 1 (range  8.10 to 9.94l
 1)), and CRP values on day
2 were also raised (median increase of 9.8mgl
 1 (range  52 to
70mgl
 1)). These generally small and transient rises from baseline
imply a mild, nonspecific inflammatory process. No changes were
seen in biochemical markers of renal function in either the liver or
kidney tumour trials. There was no change in liver function in
those patients treated in groups 2, 3 or 4. Those patients who had
deterioration in liver function were all part of group 1, and had
liver disease that was inoperable. Clinical disease progression was
seen in seven of these patients; biochemical progression was also
noted in seven patients. There were transient rises in bilirubin of
two patients, both of which settled at day 12. One patient had a
slow rise in bilirubin (not associated with an immediate post-
treatment spike), most likely related to cancer progression. AST
did rise transiently after treatment in 15 of the 22 patients (mean
rise of 22.6IUl
 1 on day 2 post-HIFU) as might be expected from a
small volume of cellular destruction. ALP rose gradually in six
patients, and LDH in five cases, but in these instances, there was
no transient rise immediately post-HIFU.
Of the 30 patients treated, 27 were evaluable in terms of response
to treatment. Evidence of ablation was seen (radiologically or
histologically) in 25 patients (93%). Of the 26 patients who had
radiological evaluation, 24 had clear zones of ablation on post-
HIFU MRI. Accuracy was assessed as ‘good’ in 21. Two patients
had zones of ablation lying 2mm in front of the target tumour, and
one patient had a zone of ablation lying 2mm beyond the target.
The data for overall radiological and histological evaluation are
given in Table 3. Examples of radiological evidence of ablation are
shown in Figures 3 and 4, for liver and kidney tumours,
respectively.
DISCUSSION
High-intensity focused ultrasound is in its infancy in the West. The
work carried out in China suggests that this modality has great
potential in the treatment of solid tumour deposits. We have
shown that extracorporeal HIFU is both a safe and feasible option
for cancer patients, with a favourable side-effect profile.




Event 0 1 2 3
Discomfort at treatment site 6 16 7 1
Skin toxicity at treatment site 22 7 1 0
Oedema at treatment site 22 3 3 2
Fever 26 3 1 0
Other 27 3 0 0
HIFU¼high-intensity focused ultrasound; CTC¼common toxicity criteria.
aNumber
of patients who experienced each adverse event by grade.
Figure 2 (A) Right chest wall. Grade 1 skin toxicity following intercostal
HIFU treatment to a liver metsastasis. (B) Close-up of lesion showing scale.
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sAll adverse events were local to the treatment site and self-
limiting. The only clinically relevant symptom encountered has
been discomfort, which although reported in 80% of cases has
generally been ‘mild’ in severity. Skin toxicity was seen in eight
cases (27%). In seven of these, toxicity consisted of pinhead
blisters or tracks that were not clinically relevant and resolved
spontaneously. Grade 2 skin toxicity was seen only in one case,
which also resolved spontaneously. Subcutaneous oedema
Figure 3 Axial FAME series MRI images, 1min post IV gadolinium
contrast. (A) Before HIFU with a right hepatic metastasis within segment
VIII showing central necrosis, and (B) 12 days after HIFU, a larger zone
consistent with coagulation necrosis within the metastasis.
Figure 4 Subtraction MRI films, taking the FAME precontrast series from
the 1min postcontrast images. Patient with a right primary renal tumour
(A) before HIFU showing contrast uptake within the target tumour, and
(B) 12 days after HIFU, showing no contrast uptake within the target
tumour, consistent with ablation.
Table 3 Results of the HIFU trials
a
Intended area of ablation (cm
2) Measured area of ablation (cm
2)
Ablation seen in Median Range Median Range
Liver
Radiologically assessed 20/20 (100%) 4.8 0.8–9.0 3.3 0.1–42.9
Histologically assessed 6/6 (100%) 5.5 3.8–7.5 5.6 0.2–16.0
Kidney
Radiologically assessed 4/6 (67%) 4.0 1.5–6.0 5.3 0.8–9.7
Histologically assessed 1/4 (25%) 4.5 — 4.8 —
HIFU¼high-intensity focused ultrasound.
aComparison of the expected area of ablation at the time of treatment with that measured on follow-up imaging or histology.
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soccurred in eight of those treated; however, none of these
occurrences were clinically relevant, and settled spontaneously.
The working party on image-guided tumour ablation identifies
‘postablation syndrome’ consisting of a self-limiting sign complex
of low-grade fever and general malaise. In all, 13% of those treated
experienced a low-grade fever, consistent with postablation
syndrome. This occurred within the first 12h and had settled
within 24h. There are other potential complications of HIFU,
including damage to adjacent viscera such as bowel or gallbladder,
and secondary infection of the resulting necrotic volume, but these
have not been observed in our patients.
Changes in laboratory values demonstrate that the physiological
consequences of HIFU upon hepatic and renal function are
minimal, even when those organs are the target. Creatinine levels
have been unaffected in the renal tumour group, an important
consideration if HIFU is to be administered to those with poor
renal reserve. Likewise, hepatic function remained stable after
HIFU, with the exception of those patients with gross metastatic
infiltration of the liver, where a decline in liver function might be
expected. The transient elevation in white cell count and CRP seen
immediately after HIFU are not clinically significant, and likely
reflect a systemic inflammatory response to the tumour ablation.
We have demonstrated that HIFU exposure results in the
creation of discrete zones of ablation in 25 of 27 targeted solid
tumour deposits. Accuracy, as assessed by MRI, showed that the
lesions were placed directly on the target tumour in 88% of cases,
and in the remainder, the ablated region lay within 5mm of the
target. It is important to put this into clinical context, as during
any cancer surgery or ablation, tumours are excised or ablated
along with a surrounding margin of normal tissue, usually no less
than 1cm. On the assumption that similar principles would apply
to HIFU treatment, all observed zones of ablation occurred with
these margins.
The radiological analysis of HIFU- (Table 3) treated liver
tumours shows that the median area of ablation seen on MRI is
45% smaller than that predicted at the time of treatment. Although
this disparity would seem to be large, the histological zones of
ablation correlate more closely with those expected. The median
area of histological ablation is 102% of the median intended area.
Liver tumours were ablated more reliably than kidney tumours.
This may be due to the greater depth of renal tumours and the
presence of a perinephric fat layer, both of which attenuate the
ultrasonic beam. For the purpose of analysis, only those renal
tumours that showed evidence of ablation either radiologically or
histologically are included in the analysis of expected vs measured
response. Again, the difference between median area of ablation
seen on MRI and intended is greater than that seen between
histological ablation and intended (25 vs 6%, respectively).
There are potential limitations to the clinical application of
HIFU, and to the planning and the actual delivery of treatment.
HIFU cannot be directed through air-filled viscera such as the lung
or bowel and other obstructions such as bone can absorb or reflect
an ultrasound beam. For this reason, tumours in the dome of the
liver are not likely to be suitable targets for HIFU, unless further
invasive procedures are performed, such as injection of saline into
the pleural cavity to produce an acoustic window (F Wu, personal
communication). Ablation of tumours lying in close proximity to
bowel or gall bladder run the risk of visceral perforation should
patient movement occur during treatment. Even in the absence of
such complicating factors, if a target tumour is situated at a depth
greater than 10cm from the skin, the attenuation of the normal
tissues in the beam-path reduces the likelihood of successful
ablation with current devices. Additional factors such as obstruc-
tion of the incident ultrasound energy by the ribs or reflection by
tissue interfaces can also lead to undertreatment. Potential
advantages and limitations are summarised in Table 4. Another
concern is that HIFU may promote the spread of metastases. Small
animal studies have shown that HIFU does not increase the risk of
metastatic spread (Oosterhof et al, 1997), and there is evidence that
ablative therapies may upregulate the response of host immune
system to subsequent tumour challenge (Yang et al, 1992; den Brok
et al, 2004).
Treatment times are longer than is desirable. A treatment
session lasting for 2h for a superficial 2–3cm tumour may be
acceptable when compared to the alternative of surgical resection,
but compares less favourably with other minimally invasive
techniques such as radiofrequency ablation. For the treatment of
large tumours, where there is no minimally invasive alternative
option, the longer treatment times may be justified on the grounds
of a lower morbidity and mortality than conventional surgery.
Despite this, it is likely that treatment times will reduce with
development of the technology, experience and in combination
with methods to reduce tumour perfusion, such as trans-arterial
embolisation (Wu et al, 2005a).
In our series, HIFU was performed under general anaesthesia to
ensure patient comfort and immobility. This is generally regarded
as a limitation, but general anaesthesia does provide a means to
control respiratory excursion in organs such as the liver and
kidney. Movement of these organs during HIFU exposure could
compromise treatment efficacy and preventing this motion over-
comes what would otherwise be a further limitation of HIFU.
Surgery for the treatment of liver and kidney tumours carries a
significant morbidity and mortality, and may be associated with
long in-patient stays and recovery periods. Extracorporeal HIFU
offers the same potential for disease control as other minimally
invasive treatments, and has the benefit of being noninvasive. In
contrast to radiotherapy, treatments can in principle be repeated,
as there is no ceiling to the number of ultrasound exposures that
normal tissues can tolerate if not at the focus of the HIFU beam.
Other groups are also generating results in different areas; an
MRI-guided extracorporeal HIFU device (Exablate, Insightec Inc.,
Haifa, Israel) has been granted FDA approval for the treatment of
Table 4 Benefits and limitations of HIFU
Benefits Limitations
Noninvasive Requires general anaesthetic
Safe – morbidity much less than surgery Long time taken to ablate given volume
Real-time imaging allows evaluation of area during treatment Position of tumours affects ability to treat
Large scope for treatment of different tumour types Local pain, oedema and skin toxicity
No risk of increased metastasis
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suterine fibroids (Stewart et al, 2003), and trans-rectal HIFU devices
are increasingly being used to treat localised prostate cancer in
Europe (Blana et al, 2004).
High-intensity focused ultrasound holds promise; however,
randomised control studies are required to evaluate the true
potential of this novel modality. There are many areas in which
HIFU may provide benefit: both in the curative setting when
compared to open or minimally invasive procedures and in
palliation, where quality of life may be improved. The studies
presented here document the safety and efficacy of this novel
treatment in a preliminary group of patients and should provide a
basis for the next phase of trials to begin.
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